POSTERS ASCO 2024

Cáncer de mama

Cáncer de mama

Metastásico

acceso

First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

Cristina Saura, MD, PhD

Vall d’Hebron University Hospital, Vall d'Hebron Institute of Oncology

acceso

Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.

María Gion, MD

Hospital Universitario Ramón y Cajal

Antonio-Llombart-Cussac

acceso

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

Antonio Llombart-Cussac, MD

Hospital Arnau de Vilanova, Valencia, Spain

acceso

Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.

Sonia Pernas, MD, PhD

Institut Català d'Oncologia, IDIBELL, L’Hospitalet

Cáncer de mama

Local, regional y adyuvante

acceso

Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers.

Isabel Blancas, MD, PhD

Oncology Department, San Cecilio University Hospital

Carlos José Rodríguez-González, MD, PhD

Oncology Department, Castellón Hospital, Castellón

Natalia-Garcia-Cesteros

acceso

Postpartum breast cancer: Analysis of factors related to pregnancy and identification of differential prognostic markers.

Natalia García Cesteros

Medical Oncology Department, University Reina Sofia Hospital

Milana-Bergamino-Sirven

acceso

Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.

Milana Bergamino Sirvén, MD, PhD

Institute of Cancer Research

Jose-Manuel-Perez-Garcia

acceso

Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

José Manuel Pérez García, MD, PhD

International Breast Cancer Center (IBCC)

Una iniciativa científica de:

Con el patrocinio de:

REGENERON